Zomedica Corp. (ZOM)
| Market Cap | 846.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.60M |
| Shares Out | 550.54M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $1.02 |
| Previous Close | $0.96 |
| Change ($) | 0.06 |
| Change (%) | 6.67% |
| Day's Open | 1.08 |
| Day's Range | 1.00 - 1.09 |
| Day's Volume | 135,715,450 |
| 52-Week Range | 0.07 - 1.30 |
The veterinary technology specialist is strengthening its distribution network.
ANN ARBOR, Mich., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica”), a veterinary health company creating point-of-care diagnostics products for dogs and cats,...
Zomedica Pharmaceuticals is likely a pump-and-dump. Don't get caught holding the bag when ZOM stock crashes back to under $1 per share.
Investors are intrigued by the popular penny stock's new razor and blade strategy.
Zomedica shares are surging after the company updated investors on a warrant-redemption cash influx and news that its end-of-March product rollout is on track. Pet-related stocks are hot and Z...
ANN ARBOR, Mich., Jan. 18, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products f...
Even with the company addressing a potentially hyper-growth market, the price action of ZOM stock is just too frothy. The post Expect This Pullback in High-Flying Zomedica Pharmaceuticals Stoc...
Traders are bailing out of the penny stock after learning that a celebrity's "endorsement" was not all it appeared to be.
A booming market for pet care could push this soaring stock even higher.
Zomedica is a development-stage company that focuses on the unmet diagnostic and therapeutic treatment needs of clinical veterinarians. The company's first product - TRUFORMA - is an innovativ...
ZOM stock continues to rocket higher. Here's what you should know about the red-hot pet care play Zomedica now.
The pet care company's new diagnostic platform could be a game changer.
A penny stock popped Monday and “Tiger King” star Carole Baskin could be the reason. What Happened: A video on YouTube shows Baskin discussing Zomedica Corp (NYSE: ZOM) and the company's upcom...
Zomedica's TRUFORMA platform could disrupt the $2.8 billion vet diagnostics market and propel ZOM stock above $3. The post Here's Why Red-Hot ZOM Stock Could Soar Another 200% appeared first o...
Investors are excited about the pet care company's upcoming product launch.
Zomedica Pharmaceuticals is riding the wave of rising pet care spending. What's got tails wagging this morning about ZOM stock?
ANN ARBOR, Mich., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products f...
Progress Continuing Toward Commercialization of TRUFORMA™ Progress Continuing Toward Commercialization of TRUFORMA™
ANN ARBOR, Mich., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products f...
Zomedica (ZOM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. A...
The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) jumped 18.27% today. Here's an explanation of why that happened.
The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) has increased by 18.38% today. What caused the stock price to increase?
We all want the best for our furry friends. That's why ZOM stock is surging higher on positive news from Zomedica Pharmaceuticals.
Certain assays under development are believed to be the first ever for use at the point-of-care and the first ever available in veterinary medicine Certain assays under development are believe...
ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”) today reported consolidated financial results for the third quarter ended Septe...
ANN ARBOR, Mich., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive Officer, has been m...
ANN ARBOR, Mich., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.) (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company cre...
ANN ARBOR, Mich., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care dia...
Zomedica Announces Letter to Shareholders in Connection With Annual and Special Virtual-Only Meeting
ANN ARBOR, Mich., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that its proxy solicitor, Alliance Advisors, mailed the following let...
ANN ARBOR, Mich., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), a veterinary health company creating point-of-care diagnostics products for companio...
Three new assays to be added to the five assays currently under development Three new assays to be added to the five assays currently under development
ANN ARBOR, Mich., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive O...
ANN ARBOR, Mich., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company, today reported consolidated f...
ANN ARBOR, Mich., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM), a veterinary health company, announced that Robert Cohen, Interim Chief ...
Penny stocks will always be risky. That said, with the huge disconnect we’re seeing in the markets, now may be a time to gamble.
Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results
Zomedica Pharmaceuticals Corp. (ZOM) closed the most recent trading day at $0.16, moving +0.57% from the previous trading session.
ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM) (TSX-V: ZOM), a veterinary health company, announced that Shameze Rampert...
Zomedica Pharmaceuticals Corp. (ZOM) closed at $0.16 in the latest trading session, marking a -0.3% move from the prior day.
Permits Validation and Pilot Program Progress During COVID-19 Restrictions Permits Validation and Pilot Program Progress During COVID-19 Restrictions
Zomedica Pharmaceuticals Corp. (ZOM) closed at $0.16 in the latest trading session, marking a +1.31% move from the prior day.
ANN ARBOR, Mich., July 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the cl...
The market might be facing turbulence, but Louis Navellier says there are three sectors that should treat investors well regardless Do you know where the term “dog days of summer” comes from...
ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the p...
ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary diagnostic company, announced today that ...
Zomedica (ZOM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Moves Closer to Development Completion of Its Novel Point-of-Care Diagnostic Platform Moves Closer to Development Completion of Its Novel Point-of-Care Diagnostic Platform
ANN ARBOR, Mich., May 29, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the clo...
About ZOM
Zomedica, a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism ... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 2015 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol ZOM |
Analyst Forecasts
According to one analyst, the rating for Zomedica stock is "Buy" and the 12-month stock price forecast is 0.50.